Neurology® Podcast

1) Non-convulsive status epilepticus and 2) Topic of the month: Bedside testing of the frontal lobes. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Alex Menze interviews Dr. Nick Johnson about his paper on non-convulsive status epilepticus. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about hallucinations in dementia with Lewy bodies. In the next part of the podcast Dr. Ted Burns interviews Dr. Russ Swerdlow for the next part of our discussion on areas of the frontal cortex for our Lesson of the Week. The participants had nothing to disclose except Drs Overman and Burns.

1) Mild Alzheimer disease and 2) Topic of the month: Bedside testing of the frontal lobes. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interviews Dr. Geoffrey Kerchner about his paper on mild Alzheimer disease. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about MRI findings in idiopathic intracranial hypertension. In the next part of the podcast Dr. Ted Burns interviews Dr. Russ Swerdlow for the next part of our discussion on the orbitofrontal cortex for our Lesson of the Week. Over the subsequent two weeks, we will continue to highlight other areas of the frontal cortex. The participants had nothing to disclose except Drs. Kerchner, Overman, and Burns.

1) Falls in Parkinson disease and 2) Topic of the month: Bedside testing of the frontal lobes. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Tiffini Voss interviews Dr. Kathy Chung about her paper on reducing falls in Parkinson disease. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about stroke in neurocysticercosis. In the next part of the podcast Dr. Ted Burns interviews Dr. Russ Swerdlow about dorsolateral prefrontal cortex for our Lesson of the Week. Over the next subsequent three weeks, we will highlight bedside testing of the frontal cortex. The participants had nothing to disclose except Drs. Voss, Chung, Overman, and Burns. Dr. Chung has received research support from a VA Career Development Award.Dr. Voss has received research support from the University of Rochester for Clinical Monitor for Phase III clinical trial.Dr. Over

1) MS quality of life and 2) Topic of the month: Aphasia. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Matthew Wong interviews Dr. Paul Grossman about his paper on MS quality of life, depression and fatigue. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about the accessory deep peroneal nerve. In the next part of the podcast Dr. Alberto Espay interviews Dr. Jerzy Szaflarski for the last part of our discussion on aphasia for our Lesson of the Week. The participants had nothing to disclose except Drs. Grossman, Overman, Espay and Szaflarski.

1) Management of headache and 2) Topic of the month: Aphasia. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Kelly Gwathmey interviews Professor Peter Goadsby about his paper on management of headache. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about electrodiagnostic features of axonal neuropathy. In the next part of the podcast Dr. Alberto Espay interviews Dr. Keith Josephs for the next part of our discussion on aphasias for our Lesson of the Week. The participants had nothing to disclose except Professor Goadsby, Drs. Overman, Espay and Josephs. Prof. Goadsby has served as a consultant for or served on a scientific advisory board for Advanced Bionics, Allergan, Inc., Almirall, Amgen, ATI, AstraZeneca, Belgian Research Council, Boehringer Ingelheim, Bristol-Myers Squibb, Boston Scientific, CoLucid Pharmaceuticals, Coherex Medical

1) Muscular dystrophy and 2) Topic of the month: Aphasia. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Elliot Dimberg interviews Dr. Richard Finkel about his paper on muscular dystrophy. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about anti-NMDA receptor antibody encephalitis. In the next part of the podcast Dr. Alberto Espay interviews Dr. Keith Josephs for the next part of our discussion on aphasias for our Lesson of the Week. Over the subsequent two weeks, we will continue to highlight the disorders of language. The participants had nothing to disclose except Drs. Dimberg, Finkel, Overman, Espay and Josephs. Dr. Dimberg serves as an editorial board member of AANEM Nerve and Muscle Junction Podcasts and as part of the Neurology® Podcast Panel, has received honoraria from ePocrates.com and Harris Interactive. Dr. Finkel serves o

1) Depression in Parkinson disease and 2) Topic of the month: Aphasia. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Russ Swerdlow interviews Dr. Massimo Filippi about his paper on depression in Parkinson disease. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about five clues to the diagnosis of inclusion body myositis...and...amphiphysin antibody-associated stiff-person syndrome. In the next part of the podcast Dr. Alberto Espay interviews Dr. Keith Josephs about post-stroke aphasias for our Lesson of the Week. Over the next subsequent three weeks, we will highlight primary progressive aphasias. The participants had nothing to disclose except Drs. Filippi, Overman, Espay and Josephs. Dr. Filippi serves on scientific advisory boards for Teva Pharmaceutical Industries Ltd. and Genmab A/S; has received funding for travel from Bayer Sch

1) Seasonal prevalence of MS and 2) New Clinical Practice Journal. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. John Scagnelli interviews Dr. Dominik Meier about his paper on MS disease activity. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about drug-induced parkinsonism...and...alteplase-associated hemi?orolingual angioedema from the e-Pearl archives. In the next part of the podcast Dr. Ted Burns interviews Dr. John Corboy about the first issue of the new Clinical Practice Journal for our Lesson of the Week. The participants had nothing to disclose except Drs. Meier, Overman, Burns and Corboy. Dr. Meier has received research support from the NIH (R01 AG022092-01 [co investigator] and NCRR P41 RR013218 [consultant]. Dr. Overman serves as Deputy Editor on the Neurology® Resident and Fellow Section editorial team and the Neurology®

1) Cerebral artery infarctions 2) Antibiotics-cause of encephalopathy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Justin Sattin interviews Dr. Adam Kelly about his paper on cerebral artery infarctions. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about highlights from the e-Pearl archive. In the next part of the podcast Dr. Matthew Flaherty interviews Dr. Steven Lewis on antibiotics as a cause of encephalopathy for our Lesson of the Week. In concluding, there is a brief statement where to find other up-to date patient information and current Patient Page. The participants had nothing to disclose except Drs. Overman, Flaherty and Lewis.

1) Nonfluent primary progressive aphasia and 2) MuSK antibodies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Farrah Mateen interviews Dr. Jonathan Rohrer about his paper on nonfluent primary progressive aphasia. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about the Stransky sign. In the next part of the podcast Dr. Beau Bruce interviews Dr. Donald Sanders about MuSK antibodies for our Lesson of the Week. The participants had nothing to disclose except Drs. Rohrer, Mateen, Overman, Bruce and Sanders. Dr. Mateen has received grant funding from the AAN/AANF 2010 Practice Research Fellowship. Dr. Rohrer has received research support from the Wellcome Trust (Clinical Research Fellowship) and Brain (Exit Scholarship).Dr. Overman serves as Deputy Editor on the Neurology(R) Resident and Fellow Section editorial team and the Neurology(R)

1) Comparative effectiveness research and 2) ACGME proposals for work duty hours. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Michael Benatar interviews Dr. Jacqueline French about her paper on comparative effectiveness research. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about Guillain-Barré-like syndrome with thallium poisoning. In the next part of the podcast Dr. Ted Burns interviews Dr. Lori Schuh about ACGME recommendations for work duty hours for our Lesson of the Week. The participants had nothing to disclose except Drs. French, Overman, and Burns. Dr. French has served on scientific advisory boards for UCB, Johnson & Johnson, Eisai Inc., Novartis, Valeant Pharmaceuticals International, Icagen, Inc., Ikano Therapeutics Inc., Sepracor Inc., and Marinus Pharmaceuticals, Inc.; has received funding for travel from UCB, Ky

1) Acute progressive neurologic decline and absence of mass lesion and 2) AAN.com and community features it provides. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Karen Roos interviews Drs. Jason Taub and Jeffrey Olson about their paper on acute progressive neurologic decline. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about unilateral photophobia or phonophobia in cluster headache. In the next part of the podcast Dr. Ted Burns interviews Dr. Daniel Hoch and Jose Merino about AAN.com and the community features it provides for our Lesson of the Week. The participants had nothing to disclose except Drs. Roos, Olson, Overman, Burns, Hoch, and Jose Merino. Dr. Roos serves as Editor-in-Chief of Seminars in Neurology, received royalties for 4 published textbooks, received funding for traveling from the AAN and other universities, and g

1) Multiple sclerosis: A meta-analytic approach 2) Ultrasound of peripheral nerves (Part 2). This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Keegan interviews Dr. Maria Pia Sormani about her paper on multiple sclerosis: A meta-analytic approach. In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about Terson syndrome. In the next part of the podcast Dr. Mary Lussier interviews Dr. Michael Cartwright for part two on peripheral nerve ultrasound for our Lesson of the Week. In concluding, there is a brief statement where to find other up-to date patient information and current Patient Page. The participants had nothing to disclose except Drs. Sormani, Keegan, Fugate, and Cartwright.

1) Mild cognitive decline 2) Ultrasound of peripheral nerves (Part 1). This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interviews Dr. Susan Landau about her paper on mild cognitive decline. In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about Doi's sign. In the next part of the podcast Dr. Mary Lussier interviews Dr. Michael Cartwright for part one on peripheral nerve ultrasound for our Lesson of the Week. The participants had nothing to disclose except Drs. Landau, Fugate, and Cartwright. Dr. Landau receives research support from the NIH (U01 AG024904 [Research specialist]).Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Cartwright receives research support from the NIH (1K23 N5062892-01A1) and has received speaker honoraria from AANEM and ASN annual meetings.

In this special podcast for the Neurology Journal, Dr. Ted M. Burns plays a dozen of the many interesting audio clips from Neurology Podcasts of the 2009-2010 academic year.

1) Diagnosis of acute ischemic stroke and 2) evidence-based medicine (Part 3). This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Brett Kissela interviews Dr. Peter Schellinger about his paper on diagnosis of acute ischemic stroke. In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about digiti quinti sign. In the next part of the podcast Dr. Michael Benatar interviews Dr. Mark Conaway for part three on evidence-based medicine probability, odds, and odds ratio for our Lesson of the Week. The participants had nothing to disclose except Drs. Kissela, Schellinger and Fugate. Dr. Kissela served on the scientific advisory board for Allergan, Inc in 2009; served as a consultant for Allergan for 2-day meeting in 2009; received honoraria from CME program and unrestricted educational grants; received research support from the NIH [R01 NS 30678], [N0

1) Depressive symptoms and risk of dementia and 2) Early history of the AAN. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. David Geldmacher interviews Dr. Jane Saczynski about her paper on depressive symptoms and risk of dementia. In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about wrong way eyes. In the next part of the podcast Dr. Ted Burns interviews Dr. Robert Joynt on the early history of the AAN for our Lesson of the Week. The participants had nothing to disclose except Drs. Fugate, Burns and Joynt. Dr. Geldmacher serves on editorial board of Brain Injury, has received speaker honoraria from Danville Regional Medical Center, Georgetown Medical School, University of Rochester, Cleveland Clinic, Kaiser Permanante and Academy for Healthcare Education, receives research support from Elan Corporation [PI], Eisai Inc. [PI], Mediva

1) Imaging in acute stroke and 2) conflicts of interest: A personal perspective. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Brett Kissela interviews Dr. Yves Samson about his paper on diffusion-weighted MR imaging in acute stroke. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about posterior vermal split syndrome. In the next part of the podcast Dr. Matthew Wong interviews Dr. Joseph Martin for our Lesson of the Week about his paper on the pervasive influence of conflicts of interest. The participants had nothing to disclose except Drs. Kissela, Samson and Martin. Dr. Kissela served on the scientific advisory board for Allergan, Inc in 2009; served as a consultant for Allergan for 2-day meeting in 2009; received honoraria from CME program and unrestricted educational grants; received research support from the NIH [R01 NS 30678], [

1) Restless legs syndrome and 2) evidence-based medicine (part 2). This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Aman Savani interviews Dr. Diego Garcia-Borreguero about his paper on restless legs syndrome. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about fatal gastroenteritis. In the next part of the podcast Dr. Michael Benatar interviews Dr. Mark Conaway for part two on evidence-based medicine relative risk, relative risk reduction, absolute risk reduction, and NNT for our Lesson of the Week. You may also want to check out the other two-part series on evidence-based medicine where Dr. Michael Benatar interviewed Dr. Gary Gronseth for our March 30 and April 6 Lesson of the Week. The participants had nothing to disclose except Dr. Garcia-Borreguero. Dr. Garcia-Borreguero has served on scientific advisory boards for and received sp

1) Embouchure dystonia and 2) progressive myoclonic encephalopathies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Robert Pascuzzi interviews Dr. Bernhard Haslinger about his paper on embouchure dystonia. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about the corneal reflex in stroke. In the next part of the podcast Dr. Alberto Espay interviews Dr. Berge Minassian for part 2 on progressive myoclonic encephalopathies for our Lesson of the Week. The participants had nothing to disclose except Drs. Haslinger, Pascuzzi and Espay. Dr. Haslinger serves on a scientific board for Merz Pharmaceuticals, LLC; has received funding from travel from Ipsen, Merz Pharmaceuticals, LLC, and Medtronic, Inc.; has received speaker honoraria from Novartis, GlaxoSmithKline, Desitin Pharmaceuticals, GmbH, Ipsen, and Allergan, Inc.; receives research suppo